These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15842352)

  • 1. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
    Wibaut-Berlaimont V; Randi AM; Mandryko V; Lunnon MW; Haskard DO; Naoumova RP
    J Thromb Haemost; 2005 Apr; 3(4):677-85. PubMed ID: 15842352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
    Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.
    Rebecchi IM; Rodrigues AC; Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Soares SA; Bertolami MC; Faludi AA; Bernik MM; Dorea EL; Dagli ML; Avanzo JL; Hirata RD
    Biochem Pharmacol; 2009 Jan; 77(1):66-75. PubMed ID: 18851956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.
    Dane-Stewart CA; Watts GF; Pal S; Chan D; Thompson P; Hung J; Mamo JC
    Metabolism; 2003 Oct; 52(10):1279-86. PubMed ID: 14564679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
    Genvigir FD; Rodrigues AC; Cerda A; Arazi SS; Willrich MA; Oliveira R; Hirata MH; Dorea EL; Bernik MM; Curi R; Hirata RD
    Pharmacogenomics; 2010 Sep; 11(9):1235-46. PubMed ID: 20860464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
    Waehre T; Damås JK; Gullestad L; Holm AM; Pedersen TR; Arnesen KE; Torsvik H; Frøland SS; Semb AG; Aukrust P
    J Am Coll Cardiol; 2003 May; 41(9):1460-7. PubMed ID: 12742282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
    Wagner AH; Gebauer M; Güldenzoph B; Hecker M
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
    Funatsu T; Kakuta H; Tanaka H; Arai Y; Suzuki K; Miyata K
    Nihon Yakurigaku Zasshi; 2001 Jan; 117(1):65-76. PubMed ID: 11233299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected].
    Naoumova RP; Patel DD; O'Neill FH; Thompson GR; Knight BL
    Eur J Clin Invest; 2003 Jan; 33(1):88-91. PubMed ID: 12492458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines.
    Neurauter G; Wirleitner B; Laich A; Schennach H; Weiss G; Fuchs D
    Clin Exp Immunol; 2003 Feb; 131(2):264-7. PubMed ID: 12562386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
    Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Dorea EL; Bernik M; Hirata RD
    Clin Chim Acta; 2008 Jul; 393(2):119-24. PubMed ID: 18435918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
    Ji G; Zhao X; Leng L; Liu P; Jiang Z
    Lipids Health Dis; 2011 Jan; 10():23. PubMed ID: 21269482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y; Ishikawa E; Shinozawa E; Shimada M; Miura S; Adachi R; Tozawa R
    Life Sci; 2014 Jul; 108(1):7-12. PubMed ID: 24805868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
    Ness GC; Chambers CM; Lopez D
    J Lipid Res; 1998 Jan; 39(1):75-84. PubMed ID: 9469588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
    Martínez-González J; Alfón J; Berrozpe M; Badimon L
    Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.